LightIntegra Technology developed ThromboLUX, a rapid, non-invasive optical test that assesses platelet activation status in about five minutes using dynamic light scattering without requiring dilution. The test determines size and distribution of particles in a platelet sample to identify which units are suited for prophylactic versus therapeutic use. The company says ThromboLUX can reduce ineffective transfusions and platelet refractoriness, improving patient outcomes, safety, and reducing healthcare costs. LightIntegra was launched from the Canadian Blood Services R&D labs out of research by Dr. Elisabeth Maurer and is privately funded. The business cites clinical context: up to 50% of platelet bag inventory may be activated and roughly 32% of platelet transfusions fail, underscoring the need for the test. The company plans to use recent funding to introduce ThromboLUX to the U.S. market. LightIntegra Technology, Inc. is a Vancouver, Canada–based medical devices company led by President and CEO Bill Dubiel. Its core product, ThromboLUX, identifies non-activated platelet products deemed optimal for cancer patients to help reduce blood transfusions and minimize platelet refractoriness. The company launched commercial sales to the U.S. market in April 2017. LightIntegra focuses on diagnostic solutions for transfusion management in oncology patients. The company recently secured financing to support its commercial expansion in the United States.

Total raised

$9M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2019